Showing 4221-4230 of 9409 results for "".
- Pfizer and GWU Renew Grant Program to Expand Teledermatology Access for Inflammatory Skin Conditionshttps://practicaldermatology.com/news/pfizer-and-gwu-renew-grant-program-to-expand-teledermatology-access-for-inflammatory-skin-conditions/2483889/Pfizer Global Medical Grants and The George Washington University (GWU) have renewed their joint grant program focused on broadening access to dermatologic care in underserved U.S. communities. According to a GWU press announc
- Analysis: Ceramide Skincare from Birth May Mitigate Pediatric ADhttps://practicaldermatology.com/news/analysis-ceramide-skincare-from-birth-may-mitigate-pediatric-ad/2483872/A new consensus paper offers clinical recommendations to address the complex interplay of skin barrier dysfunction and SAIGE (Staphylococcus aureus colonization, immunologic, genetic, and environmental) factors in pediatric atopic dermatitis (AD).
- Dr. Karan Lal Shares 'Recipe' for Prescribing GLP-1shttps://practicaldermatology.com/news/dr-karan-lal-shares-recipe-for-prescribing-glp-1s/2483869/The increasingly understood relevance of weight-loss drugs to inflammatory skin conditions was a hot topic at the Skin of Color Update in New York, New York, and Karan Lal, DO, FAAD, shared his “recipe” for addressing it with patients. Dr. Lal first checks for prior diagnoses of diabetes m
- Dr. Jennifer Soung: Ask Patient’s Permission Before Talking GLP-1shttps://practicaldermatology.com/news/dr-jennifer-soung-ask-patients-permission-before-talking-glp-1s/2483863/GLP-1 treatments have become commonplace in dermatology practices, with both aesthetic and medical dermatology implications heavily involved. Talking to patients about the latter issue, however, can prove challenging. Despite the mounting literature indicating that GLP-1 agonists can help allevia
- Latino Melanoma Patients Face Barriers to Early Diagnosis and Treatmenthttps://practicaldermatology.com/news/latino-melanoma-patients-face-barriers-to-early-diagnosis-and-treatment/2483846/A new qualitative study published in JAMA Dermatology explored persistent disparities Latino patients face in timely melanoma diagnosis and treatment, despite advances in therapy that have improved survival among non-Hispani
- FDA Approves Guselkumab for Children 6 and Older With PsOhttps://practicaldermatology.com/news/fda-approves-guselkumab-for-children-6-and-older-with-pso/2483604/The US Food and Drug Administration (FDA) has approved guselkumab (Tremfya®, Johnson & Johnson) for the treatment of children 6 and older, weighing at least 40 kg, with moderate-to-severe plaque psoriasis (PsO) or active psoriatic arthritis (PsA), making it the
- LEO Pharma Finalizes Acquisition of Spevigo® for Rare Dermatologic Diseaseshttps://practicaldermatology.com/news/leo-pharma-finalizes-acquisition-of-spevigo-for-rare-dermatologic-diseases/2483600/LEO Pharma has officially completed its acquisition of Spevigo® (spesolimab) from Boehringer Ingelheim, according to a press release from the manufacturer. The purchase represents the c
- Accelerated Phenotypic Aging Linked to Increased Mortality With PsOhttps://practicaldermatology.com/news/accelerated-phenotypic-aging-linked-to-increased-mortality-with-pso/2483591/A new analysis of US adult data has found that phenotypic age acceleration (PhenoAge-accel) is associated with increased risk of psoriasis and—when coexisting with the disease—elevated risk of all-cause and cardiovascular disease (CVD) mortality. The study, publishe
- Roflumilast Phase 2 Results for Children Consistent With Phase 3 Adult Trialshttps://practicaldermatology.com/news/roflumilast-phase-2-results-for-children-consistent-with-phase-3-adult-trials/2483558/Once-daily roflumilast cream 0.3% was well tolerated and improved signs and symptoms of psoriasis in children 2 to 11 years old in two 4-week, phase 2, open-label, maximal usage pharmacokinetic and safety studies, according to an article published in Pediatric Dermatology. The res
- IFPA Highlights Patient Voices in Global Health Policy at UN Panelhttps://practicaldermatology.com/news/ifpa-highlights-patient-voices-in-global-health-policy/2483540/The International Federation of Psoriatic Disease Associations (IFPA) issued a call to global policymakers to recognize psoriatic disease as a serious noncommunicable disease (NCD) with system-wide implications at the 80th UN General Assembly in New York.